Evidence map›Paper›PMID 28212428›Full record

ArticlePloS one2017

A novel hemagglutinin protein produced in bacteria protects chickens against H5N1 highly pathogenic avian influenza viruses by inducing H5 subtype-specific neutralizing antibodies.

Violetta Sączyńska, Agnieszka Romanik, Katarzyna Florys, Violetta Cecuda-Adamczewska, Małgorzata Kęsik-Brodacka, Krzysztof Śmietanka, Monika Olszewska, Katarzyna Domańska-Blicharz, Zenon Minta, Bogusław Szewczyk and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Violetta SączyńskaInstitute of Biotechnology and Antibiotics, Warsaw, Poland.
Agnieszka RomanikInstitute of Biotechnology and Antibiotics, Warsaw, Poland.
Katarzyna FlorysInstitute of Biotechnology and Antibiotics, Warsaw, Poland.
Violetta Cecuda-AdamczewskaInstitute of Biotechnology and Antibiotics, Warsaw, Poland.
Małgorzata Kęsik-BrodackaInstitute of Biotechnology and Antibiotics, Warsaw, Poland.
Krzysztof ŚmietankaDepartment of Poultry Diseases, National Veterinary Research Institute, Puławy, Poland.
Monika OlszewskaDepartment of Poultry Diseases, National Veterinary Research Institute, Puławy, Poland.
Katarzyna Domańska-BlicharzDepartment of Poultry Diseases, National Veterinary Research Institute, Puławy, Poland.
Zenon MintaDepartment of Poultry Diseases, National Veterinary Research Institute, Puławy, Poland.
Bogusław SzewczykDepartment of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.
Grażyna PłucienniczakInstitute of Biotechnology and Antibiotics, Warsaw, Poland.
Andrzej PłucienniczakInstitute of Biotechnology and Antibiotics, Warsaw, Poland.
Instytut Biotechnologii i Antybiotyków · PLNational Veterinary Research Institute · PLGdańsk Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The highly pathogenic (HP) H5N1 avian influenza viruses (AIVs) cause a mortality rate of up to 100% in infected chickens and pose a permanent pandemic threat. Attempts to obtain effective vaccines against H5N1 HPAIVs have focused on hemagglutinin (HA), an immunodominant viral antigen capable of eliciting neutralizing antibodies. The vast majority of vaccine projects have been performed using eukaryotic expression systems. In contrast, we used a bacterial expression system to produce vaccine HA protein (bacterial HA) according to our own design. The HA protein with the sequence of the H5N1 HPAIV strain was efficiently expressed in Escherichia coli, recovered in the form of inclusion bodies and refolded by dilution between two chromatographic purification steps. Antigenicity studies showed that the resulting antigen, referred to as rH5-E. coli, preserves conformational epitopes targeted by antibodies specific for H5-subtype HAs, inhibiting hemagglutination and/or neutralizing influenza viruses in vitro. The proper conformation of this protein and its ability to form functional oligomers were confirmed by a hemagglutination test. Consistent with the biochemical characteristics, prime-boost immunizations with adjuvanted rH5-E. coli protected 100% and 70% of specific pathogen-free, layer-type chickens against challenge with homologous and heterologous H5N1 HPAIVs, respectively. The observed protection was related to the positivity in the FluAC H5 test (IDVet) but not to hemagglutination-inhibiting antibody titers. Due to full protection, the effective contact transmission of the homologous challenge virus did not occur. Survivors from both challenges did not or only transiently shed the viruses, as established by viral RNA detection in oropharyngeal and cloacal swabs. Our results demonstrate that vaccination with rH5-E. coli could confer control of H5N1 HPAIV infection and transmission rates in chicken flocks, accompanied by reduced virus shedding. Moreover, the role of H5 subtype-specific neutralizing antibodies in anti-influenza immunity and a novel correlate of protection are indicated.

Indexed as

Antibody SpecificityChickensAmino Acid SequenceAnimalsAntibodies, NeutralizingEscherichia coli ProteinsHemagglutininsImmunity, HumoralInfluenza A Virus, H5N1 SubtypeSpecies SpecificityAntibodies, NeutralizingEscherichia coli ProteinsHemagglutinins

Identifiers

PMID28212428
PMCPMC5315377
OpenAlexW2588732844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.